

Comparative Cardiovascular and Hypoglycaemic Safety of Glimepiride in Type 2 Diabetes: A Population-Based Cohort Study.

Antonios Douros A, et al. Diabetes Obes Metab. 2020 Feb; 22(2):254-262.

- This study has included all sulphonylurea new users between 1998 and 2017 from the UK Clinical Practice Research Datalink.
- During a mean follow-up of 1.3 years, glimepiride was associated with a similar incidence of myocardial infarction and ischaemic stroke compared with other second-generation sulphonylureas.

Glimepiride was associated with a lower incidence of all-cause mortality compared with other second-generation sulphonylureas.

